Compare LGVN & OPTT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGVN | OPTT |
|---|---|---|
| Founded | 2014 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 83.5M |
| IPO Year | 2021 | 2006 |
| Metric | LGVN | OPTT |
|---|---|---|
| Price | $0.68 | $0.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $3.00 | $1.50 |
| AVG Volume (30 Days) | 431.0K | ★ 2.6M |
| Earning Date | 05-08-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.76 | ★ 63.83 |
| EPS | N/A | ★ N/A |
| Revenue | $709,000.00 | ★ $5,861,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.81 | $221.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 6.08 |
| 52 Week Low | $0.48 | $0.29 |
| 52 Week High | $1.80 | $0.90 |
| Indicator | LGVN | OPTT |
|---|---|---|
| Relative Strength Index (RSI) | 27.71 | 40.76 |
| Support Level | $0.61 | $0.30 |
| Resistance Level | $0.84 | $0.39 |
| Average True Range (ATR) | 0.05 | 0.01 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 10.32 | 11.72 |
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Ocean Power Technologies Inc provides intelligent maritime solutions and services that enable safer, cleaner, and more productive ocean operations for the defense and security, oil and gas, science and research, and offshore wind markets. It provides ocean data collection and reporting, marine power, offshore communications, and Maritime Domain Awareness System (MDAS) products, integrated solutions, and consulting services. The company offers its products and services to a wide range of customers, including those in government and offshore energy, oil and gas, construction, wind power, and other industries. The company has operations in North and South America, Europe, Asia and Australia.